Description

1. Product Overview:
Pemrest® is an injectable formulation of Pemetrexed Disodium, an antifolate chemotherapeutic agent used in the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).

2. Composition:
Active Ingredient: Pemetrexed Disodium | Dosage Form: Injection (Lyophilized Powder)

3. Pharmacological Class:
Antifolate Antineoplastic Agent

4. Mechanism of Action:
Pemetrexed inhibits multiple folate-dependent enzymes involved in purine and pyrimidine synthesis, leading to inhibition of DNA and RNA synthesis and ultimately cancer cell death.

5. Indications:
Non-small cell lung cancer (NSCLC) | Malignant pleural mesothelioma | Maintenance therapy in advanced lung cancer

6. Dosage & Administration:
As prescribed by oncologist | Intravenous infusion only | Administered in combination with other chemotherapy agents | Dose based on body surface area

7. Clinical Benefits:
Slows tumor growth | Improves survival in NSCLC and mesothelioma | Effective in combination therapy regimens | Reduces cancer progression

8. Contraindications:
Hypersensitivity to Pemetrexed or any component | Severe renal impairment

9. Precautions:
Monitor blood counts regularly | Risk of myelosuppression | Renal function monitoring required | Folic acid and vitamin B12 supplementation required during therapy | Use under specialist supervision

10. Drug Interactions:
NSAIDs and nephrotoxic drugs may increase toxicity risk | Interactions with other chemotherapeutic agents possible

11. Special Populations:
Pregnancy: Contraindicated | Lactation: Not recommended | Pediatric: Safety not established | Elderly: Requires careful dose adjustment

12. Adverse Effects:
Fatigue | Nausea | Vomiting | Anemia | Neutropenia | Rash | Elevated liver enzymes

13. Storage Conditions:
Store below 25°C | Protect from light and moisture | Reconstituted solution to be used as directed | Keep out of reach of children

14. Packaging:
Vial (Injection powder for reconstitution)

15. Manufacturer:
Everest Pharmaceutical Ltd.